Titre du document / Document title

Prophylactic tamsulosin (flomax) in patients undergoing prostate ¹²⁵I brachytherapy for prostate carcinoma : Final report of a double-blind placebo-controlled randomized study

Auteur(s) / Author(s)

ELSHAIKH Mohamed A. ; ULCHAKER James C. ; REDDY Chandana A. ; ANGERMEIER Kenneth W. ; KLEIN Eric A. ; CHEHADE Nabil ; ALTMAN Andrew ; CIEZKI Jay P. ;

Résumé / Abstract

Purpose: To evaluate the effectiveness of prophylactic tamsulosin (Flomax) in reducing the urinary symptoms in patients undergoing ^12SI prostate implantation (PI) for prostate adenocarcinoma. Methods and Materials: This is a single-institution, double-blind, placebo-controlled, randomized trial for patients undergoing PI for prostate adenocarcinoma comparing prophylactic tamsulosin versus placebo. Eligibility criteria included patients not taking tamsulosin or other α-blockers treated with PI. The patients were randomly assigned to either tamsulosin (0.8 mg, orally once a day) or matched placebo. All patients started the medication 4 days before PI and continued for 60 days. The American Urologic Association (AUA) symptom index questionnaire was used to assess urinary symptoms. The AUA questionnaire was administered before PI for a baseline score and weekly for 8 weeks after PI. Patients were taken off the study if they developed urinary retention, had intolerable urinary symptoms, or wished to discontinue with the trial. Results: One hundred twenty-six patients were enrolled in this study from November 2001 to January 2003 (118 were evaluable: 58 in the tamsulosin arm and 60 in the placebo group). Pretreatment and treatment characteristics were comparably matched between the two groups. The urinary retention rate was 17% (10 patients) in the placebo group compared with 10% (6 patients) in the tamsulosin group (p = 0.3161). Eighty-eight percent (14 patients) of those who developed urinary retention experienced it within 2 weeks after the PI. Intolerable urinary symptoms were reported equally (10 patients in each group) with 70% occurring in the first 2 weeks after PI. There was a significant difference in mean AUA score in favor of tamsulosin at Week 5 after PI (p = 0.03). Conclusions: Prophylactic tamsulosin (0.8 mg/day) before prostate brachytherapy did not significantly affect urinary retention rates, but had a positive effect on urinary morbidity at Week 5 after PI.

Revue / Journal Title

International journal of radiation oncology, biology, physics   ISSN 0360-3016   CODEN IOBPD3 

Source / Source

2005, vol. 62, n^o1, pp. 164-169 [6 page(s) (article)]

Langue / Language

Anglais

Editeur / Publisher

Elsevier, New York, NY, ETATS-UNIS  (1975) (Revue)

Localisation / Location

INIST-CNRS, Cote INIST : 17180, 35400012956356.0210